Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Thomas

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusionDouglas G McNeel, Jens Eickhoff, Fred T Lee, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|August 16, 2014
Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argumentThejus T Jayakrishnan, Hasan Nadeem, Ryan T Groeschl, et al.
Therapeutic Advances in Medical Oncology|May 21, 2024
Chemotherapy-free treatment targeting fusions and driver mutations in <i>KRAS</i> wild-type pancreatic ductal adenocarcinoma, a case seriesMaahum Mehdi, Aniko Szabo, Aditya Shreenivas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancerGrace K Dy, James P Thomas, George Wilding, et al.
Cancer Research|October 24, 2025
Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal AdenocarcinomaMandana Kamgar, G Aaron Hobbs, Raven Davidson, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusionDouglas G McNeel, Jens Eickhoff, Fred T Lee, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|August 16, 2014
Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argumentThejus T Jayakrishnan, Hasan Nadeem, Ryan T Groeschl, et al.
Therapeutic Advances in Medical Oncology|May 21, 2024
Chemotherapy-free treatment targeting fusions and driver mutations in <i>KRAS</i> wild-type pancreatic ductal adenocarcinoma, a case seriesMaahum Mehdi, Aniko Szabo, Aditya Shreenivas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancerGrace K Dy, James P Thomas, George Wilding, et al.
Cancer Research|October 24, 2025
Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal AdenocarcinomaMandana Kamgar, G Aaron Hobbs, Raven Davidson, et al.
Pageof 5